Article
Author(s):
The FDA has approved a new indication for adalimumab (Humira) to treat pediatric patients age 6 years and older afflicted with moderately to severely active Crohn's disease.
AbbVie announced today that the FDA has approved a new indication for adalimumab (Humira) to treat pediatric patients age 6 years and older afflicted with moderately to severely active Crohn’s disease who have not responded adequately to prior treatment with corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.
This expanded approval makes Humira the first and only at-home biologic treatment approved for use in pediatric patients with Crohn’s disease, a type of inflammatory bowel disease (IBD) characterized by symptoms that include abdominal pain, weight-loss, and diarrhea.
To read the full story from HCPLive.com, click here.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children At Increased Risk